Advancing Patients' Care

PacePress | CoolCryo | MiniMax | AtriClamp

Corporate presentation

April 2026

Mission

We develop advanced solutions to support patients with cardiovascular diseases



LEGAL NOTICE

This document has been prepared for information purposes only. It does not constitute an advertisement or offer of securities in public trading. It uses sources of information that Medinice S.A. considers as reliable and accurate, but there is no guarantee that they are comprehensive and fully reflect the facts. The study may contain forward-looking statements that represent investment risk or a source of uncertainty and may differ materially from actual results. Medinice S.A. is not responsible for the effects of decisions that were taken on the basis of this study. Responsibility rests solely with the users of the study. The study is protected by the Act on Copyright and Related Rights. Reproduction, publication or distribution requires the written consent of Medinice S.A..

Founders

Sanjeev Choudhary

Co-Founder
Chief Executive Officer

Prof. Piotr Suwalski MD, PhD

Co-Founder / Co-Inventor
Chairman of the Scientific Board

MEDINICE S.A.

Founded in 2012 by renowned medical specialists and an experienced entrepreneur.

Develops, creates, and commercializes advanced technologies for the treatment of cardiovascular diseases.

Listed on the Warsaw Stock Exchange since 2018.

Holds ISO 13485.

About Company

17 PLN milions	obtained from grants
67 PLN milions	obtained from the issue of shares
568 PLN milions	value of projects*
60+	patents and applications
4	implemented projects

22% founders	14% TFI PZU	64% others

* In February 2026, Trigon DM prepared a project valuation of PLN 568 million.

** As of December 31, 2025, the Group employed 11 people (one fewer than on December 31, 2024).

Management Team



Sanjeev Choudhary

Co-founder
President of the Management Board (CEO)

Over 25 years of professional experience in mergers and acquisitions (M&A), business scaling, and strategic leadership.

Absolwent Ashridge Business School, INSEAD oraz Centre for Creative Leadership



Grzegorz Wróblewski, PhD

Chief Technology Officer (CTO)

Over 15 years of experience in Research & Development (R&D)
Author of over 50 scientific publications.

Developer of technology implemented by Medtronic.
Author of 4 medical devices (Class II and III).



Piotr Łoziński

Chief Financial Officer (CFO)

Over 15 years of experience in finance in leadership roles within the medical device and FMCG sectors.

M&A advisory. Successfully conducted equity and debt financing rounds. Fellow Member of ACCA and the Institute of Internal Auditors.

Robert Bzowski

Director of Quality & Regulations

Over 25 years of experience in medical device industry, including QMS, CSV, validation, and implementation.

Numerous inspections by the FDA, notified bodies, and international regulatory agencies, as well as safety certification audits.

Scientific Board

CARDIAC SURGERY

Prof. Piotr Suwalski MD

Director of National Medical Institute of MIA in Poland. Former president of ISMICS, member of ESC i EACTS, 21CCSS.

Prof. Valavanur Subramanian MD, PhD

Head of Lenox Hill Cardiac Surgery - Manhattan. Pioneer of minimally invasive cardiac surgery. Founder of ISMICS

Prof. Paul Gründeman MD, PhD

Professor at Utrecht Medical Center. Co-inventor of the Octopus® device.

ELECTRO PHISIOLOGY

Prof. Pawel Balsam MD, PhD

Head of the Clinical Department of Electrocardiology at WUM. Winner of the "Super Talents of Medicine" award.

Prof. Michael Glikson MD, PhD

Director at CCEF and SUNY Downstate Hospital, New York. Former president of Israel Heart Society.

Prof. Adam Budzikowski MD, PhD

Director at CCEF and SUNY Downstate Hospital, New York. Member of the PSC and ESC and HRS.

Pipeline of wide range innovative medical devices

AtriClamp

epicardial
LAAO device

MiniMax®

RF ablation catheter
offering 3D mapping and
cooling

CoolCryo®

quick & powerful
epi- & endocardial
cryoablation

PacePress®

prevention of
hematoma after
CIED implants

PROTOTYPING R&D

PRECLINICAL TESTING

READY TO-GO-TO MARKET
FDA Certified

READY TO-GO-TO MARKET
CE MDR certified

Project Status 2026

	Project Phase	Regulatory Status	Commercialization
CoolCryo®	MDR - recruitment completed in clinical trial (Q4'25)	**FDA 510(k) Clearance Received**	Commercial readiness
PacePress®	MDR - completion of clinical trial and positive report (Q3'25)	**MDR - CE audit (Q2'26)**	Commercial readiness
AtriClamp	R&D technology validation (Q4'25). Pre-clinical pilot (Q1'26)	FDA - confirmed 510(k) pathway. MDR - clinical trial (2027+)	Commercial readiness - 2027/2028
MiniMax®	R&D partnering with Cornav (Q3'25)	FDA / MDR - to be confirmed	JV potential with Cornav and Exit

Cardiovascular Diseases

60 mln people worldwide suffer from arrhythmia

Arrhythmia ranks among the most prevalent heart conditions. It can result in circulatory failure and strokes.
The preferred treatment approach is ablation.

Currently, ablation treatments include:

- Cryoablation (CoolCryo®) – freezing method
- Radiofrequency (MiniMax®) or Pulsed Field – burning method



PacePress®

Smart Pressure. Confident Recovery.

PACEPRESS®

Safer and faster recovery after implantations of Cardiac Implantable Electronic Devices (CIED)

PacePress is pneumatic therapeutic medical device designed to minimize the risk of complications after CIED implantations, while ensuring patient comfort, mobility and recovery.

Key features

- Reduces the risk of complications: infection and hematomas
- Shortens hospitalization
- Increases patient control and safety

1.5 million CIED procedures are performed annually worldwide. Market size is estimated at USD 1.5 billion.

CE

CE Marking
a Medical Device

CIED Postoperative Complications

1.5 million procedures performed annually worldwide



About 60% of patients undergoing CIED implantation procedures are at risk of postoperative complications. Approximately 10% of CIED procedures result in chest cavity haematomas, potentially leading to infection and re-operation.

Current prevention methods include:

- patient immobilization
- applying pressure to the implantation site



CIED Market – PacePress®

Number of CIED procedures

700K **600K** **60K**



https://www.marketresearchfuture.com/reports/cardiac-implantable-electronic-device-market-27577

- According to the American Heart Association, there are approximately 6.5 million people in the United States eligible for pacemaker implantation. Globally, this represents a potential of over 30 million procedures after which the use of PacePress® would be required.
- The number of pacemaker implantations indicates the potential demand for the therapeutic medical device PacePress®, as after each such procedure a pressure dressing is required to reduce the risk of hematoma formation in the pocket created for cardiac electrotherapy devices.

- Complications in the form of hematoma double the length of hospital stay; therefore, their elimination allows for performing twice as many procedures and generates cost savings through shorter hospitalization.
- As expected, this market is projected to grow steadily over the long term due to the aging population trend and, consequently, the overall increase in the number of patients treated in clinics and hospitals.

CoolCryo®

CoolCryo®

Faster and more efficient cardiac cryoablation system

The CoolCryo® system is designed for the cryosurgical treatment of arrhythmic cardiac tissue ablation by freezing target tissues, inducing an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway. Using liquid nitrogen makes cryoablation faster and more cost-effective.

Key features:

- at least four times faster and more efficient cryoablation
- possibility of minimally invasive endoscopic surgery
- possibility of continuous cryoablation and defrosting
- possibility of full-wall ablation of even thick tissues
- cheaper and more efficient cooling medium

Over 1 million cardiac ablations annually.
US EP mapping and ablation devices market:
USD 10.47B (2024) to USD 23.11B (2033).

510k Review – Procedure After Submission of the Application



Submission

The FDA receives our application

Acknowledgement Letter

The FDA sends a confirmation of receipt of the application or issues a request for additional information (payment, identification)

Acceptance Review

The lead reviewer checks whether the electronic eSTAR submission is complete and meets the minimum requirements for further review

Substantive Review

The application undergoes a substantive review, and after 60 days, the FDA communicates whether it will proceed under one of the following pathways:

1. Interactive Review
2. Additional Information

Decision Letter

The FDA informs about the decision on whether the device under review is substantially equivalent to the predicate device or not.

FDA 510(k) clearance obtained

Referencje:
1) FDA: 510(k) Submission Process, 10.03.2022

MiniMax®

MINIMAX®

Versatile RF ablation catheter offering 3D mapping and cooling

MiniMax® is a steerable, minimally invasive 2-in-1 catheter developed for the treatment of cardiac arrhythmias during RF ablation procedure.
It combines ablation and 3D mapping functions to reduce both the risk and duration of the procedure.
Additionally, it features cooling system using NaCl.



Key features:

- 2 in 1 – Ablation + 3D electro-anatomical mapping
- Safer procedure – shorter time and lower risk
- Advanced NaCl cooling
- Flexible and steerable tip
- X-ray free – modern visualization



RF ablation market: 1M+ procedures performed annually; market size about USD 5.5B.

Cryoablation and Radiofrequency Ablation Market - CoolCryo® & MiniMax®



Size and growth of the cardiac ablation market:

- The cardiac ablation market was valued at **USD 3.5 billion in 2022** and is projected to grow at a **CAGR of 13.5% over the next decade.**
- The valuation of the surgical cardiac ablation segment is estimated at around USD 1 billion (it is estimated that cryoablation accounts for 40-50% of this segment).

Key trends:

- Increasing number of patients with cardiovascular diseases, including cardiac arrhythmias.
- Minimally invasive procedures are the latest trend.
- Technological advancements in cardiac ablation devices.

Number of surgical ablation procedures in the US:





Exponential growth in the number of procedures:

- Concomitant surgical ablation is currently a Class I recommendation for all patients undergoing their first elective cardiac surgery.
- Europe shows similarly favorable growth trends.

https://www.gminsights.com/industry-analysis/cardiac-ablation-market?

AtriClamp

Stroke prevention in a simple step.

Stroke Prevalence Increasing Across the World

Arrhythmia and Atrial fibrillation (AF): 60 million people with arrythmia globally, approx. 5x higher risk of stroke.

Stroke incidence: 15+ million new cases per year worldwide. Top 3 cause of all deaths.

Inefficient current approach:
Lifelong anticoagulation resulting in chronic bleeding exposure and adherence burden.



Source: Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019:
https://pubmed.ncbi.nlm.nih.gov/34487721/

LAAC Provides Signigicant Stroke Reduction

Surgical closure of the left atrial appendage

Eliminates the primary source of clot formation in atrial fibrillation.

LAAC procedure concomitant to cardiac surgery

Effectively reduces the risk of ischemic stroke by over 90%.

One-time procedure without lifelong anticoagulation

Reduces bleeding risk, long-term therapy burden, and patient non-compliance.



ATRICLAMP

Stroke prevention in a simple step.

Source: [1] Petersen, J., Efficacy of four different left atrial appendage closure techniques during cardiac surgery-A transesophageal echocardiography follow-up study, JTCVS Techniques (2024).

Core Competitive Avantages

	Atriclamp	AtriClip	Penditure
Ability to reposition the same clip (potential lower risk of adverse events)	☑	☒	☒
No need to thread through the left atrial appendage (potential lower risk of clot realease)	☑	☒	☑
Cost-efficient and scalable	☑	☒	☒
Clip is not in the blood stream (lower risk of post-procedure complications)	☑	☑	☑
LAA is electrically isolated (no need for separate ablation)	☑	☑	☑
Magnetic resonance imaging compatibility (MRI conditional)	☑	☒	☒

Unsaturated Marked with Strong Growth Dynamics

Global Market of LAAC Devices (USD Billion)



Source: https://www.precedenceresearch.com/vascular-closure-devices-market

*existing CAGR estimates above 30%

1. Growing population of patients with arrhythmia

More than 60 million patients with arrhythmia worldwide; the prevalence of atrial fibrillation (AF) is increasing at a very rapid pace

2. Guideline-Driven Adoption

Top-tier US and EU guideline recommendations are accelerating global LAAC adoption.

3. Prophylactic LAAC for Stroke Prevention

Shift towards prophylactic LAA closure for cardiac surgery patients without pre-operative AF.

Potential for the market expansion up to 2 million procedures yearly (7x increase).

Strategic Acquirers Have Paid $300M–$400M+ for LAA Systems

J&J

Laminar (2023)
$400 M + milestones

Boston Scientific

WATCHMAN (2011)
$375 M

AtriCure

SentreHEART (2019)
$300 M

Medtronic

Penditure (2023)
Not Disclosed

Biosense Webster®
a Johnson & Johnson company

Coherex Medical (2015)
Not Disclosed

LAAC is a proven acquisition category for strategic medtech buyers.

Cardiac Market

LAAO market
$2 B market size



AtriClamp

300 mln USD
acquisition of SentreHEART by AtriCure in 2019

RF Ablation market
1 M+ procedures annually
$5.5 B market size

MiniMax®

125 mln USD
w 2023 MACOM acquisition of Wolfspeed RF portfolio

Cryoablation market
$800 M market size

CoolCryo®

150 mln USD
JapanLifeline acquired CardioFocus in 2020

CIED market
1.5 M procedures annually
$1.5 B market size

PacePress®

125 mln USD
ConvaTec acquired Triad Life Sciences in 2022

Summary

Repeatable revenue model

Growing demand

- Growing demand for minimally invasive technologies
- Ageing population

An experienced team

- Scientific Council composed of world-renowned scientists and inventors
- Experienced management and project teams

Competitive advantages

- Diversified portfolio
- Patent protection future projects for development

Large and healthy target market

- Potential buyers are global corporations
- The technologies under development fit in the portfolio of potential counterparties

Two projects near commercialisation

Thank you

www.medinice.pl